^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ETBX-021

    i
    Associations
    News

    Trials

    Company:
    ImmunityBio
    Drug class:
    HER2 inhibitor, Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer (NCT02751528)
    Phase 1
    NantBioScience, Inc.
    Unknown status
    Last update posted :
    08/28/2019
    Initiation :
    12/01/2016
    Primary completion :
    07/01/2020
    Completion :
    12/01/2020
    HER-2
    |
    HER-2 expression
    |
    ETBX-021